ChiCTR2600120481 版本V1.0 版本创建时间2026/03/16 10:35:23 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600120481 

最近更新日期:

Date of Last Refreshed on:

2026-03-16 10:35:16 

注册时间:

Date of Registration:

2026-03-16 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

不同诱导方案对喉罩置入效果的影响:一项基于咽部阻力评分的前瞻性随机对照研究

Public title:

Effect of Different Induction Protocols on Laryngeal Mask Placement: A Prospective Randomized Controlled Trial Based on Pharyngeal Resistance Score

注册题目简写:

English Acronym:

研究课题的正式科学名称:

不同诱导方案对喉罩置入效果的影响:一项基于咽部阻力评分的前瞻性随机对照研究

Scientific title:

Effect of Different Induction Protocols on Laryngeal Mask Placement: A Prospective Randomized Controlled Trial Based on Pharyngeal Resistance Score

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张龙 

研究负责人:

张龙 

Applicant:

Long Zhang 

Study leader:

Long Zhang 

申请注册联系人电话:

Applicant telephone:

+86 13685737816

研究负责人电话:

Study leader's
telephone:

+86 575 87996056

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

nblylmz@126.com

研究负责人电子邮件:

Study leader's E-mail:

nblylmz@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国浙江省宁波市鄞州区中山东路1059号

研究负责人通讯地址:

中国浙江省宁波市鄞州区中山东路1059号

Applicant address:

No. 1059, Zhongshan East Road, Yinzhou District, Ningbo, Zhejiang, China

Study leader's address:

No. 1059, Zhongshan East Road, Yinzhou District, Ningbo, Zhejiang, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

宁波市第六医院

Applicant's institution:

Ningbo Sixth Hospital

研究负责人所在单位:

宁波市第六医院

Affiliation of the Leader:

Ningbo Sixth Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

甬六医伦审2025论第74号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

宁波市第六医院伦理委员会

Name of the ethic committee:

Ethics Committee of Ningbo Sixth Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-11-24 00:00:00

伦理委员会联系人:

季远见

Contact Name of the ethic committee:

Ji Yuanjian

伦理委员会联系地址:

中国浙江省宁波市鄞州区中山东路1059号

Contact Address of the ethic committee:

No. 1059, Zhongshan East Road, Yinzhou District, Ningbo, Zhejiang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 574 87996165

伦理委员会联系人邮箱:

Contact email of the ethic committee:

1024522771@qq.com

研究实施负责(组长)单位:

宁波市第六医院

Primary sponsor:

Ningbo Sixth Hospital

研究实施负责(组长)单位地址:

中国浙江省宁波市鄞州区中山东路1059号

Primary sponsor's address:

No. 1059, Zhongshan East Road, Yinzhou District, Ningbo, Zhejiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

宁波市第六医院

具体地址:

中国浙江省宁波市鄞州区中山东路1059号

Institution
hospital:

Ningbo Sixth Hospital

Address:

No. 1059, Zhongshan East Road, Yinzhou District, Ningbo, Zhejiang, China

经费或物资来源:

Source(s) of funding:

None

研究疾病:

无  

Target disease:

None

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究旨在通过前瞻性随机对照试验,基于PRS,深入探讨肌松药对喉罩置入的影响,为临床麻醉实践提供更为科学、可靠的依据。  

Objectives of Study:

This study aims to conduct a prospective randomized controlled trial based on PRS to deeply explore the impact of muscle relaxants on laryngeal mask placement, providing more scientific and reliable evidence for clinical anesthesia practice.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.ASA I~III级; 2.BMI = 18.5~30 kg/m^2; 3.需喉罩通气的全身麻醉下肩关节镜或膝关节镜手术; 4.能充分理解本研究并签署知情同意书;

Inclusion criteria

1.ASA grade I to III; 2.BMI = 18.5~30 kg/m^2; 3.Surgery of shoulder arthroscopy or knee arthroscopy with laryngeal mask ventilation; 4.Fully understand this study and sign the informed consent form;

排除标准:

1.反流高危(如食管裂孔疝);
2.预计插管困难(如甲颏距<6 cm);
3.已确诊为研究相关药物过敏或禁忌者;
4.喉部手术史患者;
5.已参加其他临床试验者;
6.不能完全理解或配合完成各项随访者;

Exclusion criteria:

1.High risk of reflux (e.g., hiatal hernia);
2.Anticipated difficult intubation (e.g., thyromental distance <6 cm);
3.Diagnosed with allergies or contraindications to the investigational drug;
4.Patients with a history of throat surgery;
5.Participants in other clinical trials;
6.Unable to fully understand or cooperate with follow-up procedures;

研究实施时间:

Study execute time:

From 2025-11-01 00:00:00 To 2027-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-01 00:00:00 To 2026-12-31 00:00:00

干预措施:

Interventions:

组别:

A组

样本量:

113

Group:

Group A

Sample size:

干预措施:

麻醉诱导时,罗库溴铵0.6 mg/kg

干预措施代码:

Intervention:

During anesthesia induction, rocuronium 0.6 mg/kg

Intervention code:

组别:

C组

样本量:

113

Group:

Group C

Sample size:

干预措施:

麻醉诱导时,等体积生理盐水

干预措施代码:

Intervention:

During anesthesia induction, an equal volume of normal saline

Intervention code:

组别:

咽部阻力评分量表验证组

样本量:

20

Group:

Validation Group of the Pharyngeal Resistance Scoring Scale

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

B组

样本量:

113

Group:

Group B

Sample size:

干预措施:

麻醉诱导时,罗库溴铵0.3 mg/kg+等量生理盐水稀释

干预措施代码:

Intervention:

During anesthesia induction, rocuronium 0.3 mg/kg diluted with an equal volume of normal saline

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

宁波市第六医院 

单位级别:

三级甲等 

Institution
hospital:

Ningbo Sixth Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

气道平台压

指标类型:

次要指标

Outcome:

Airway plateau pressure

Type:

Secondary indicator

测量时间点:

喉罩置入后

测量方法:

仪器测量

Measure time point of outcome:

After laryngeal mask insertion

Measure method:

Instrument measurement

指标中文名:

复苏时间

指标类型:

次要指标

Outcome:

Recovery time

Type:

Secondary indicator

测量时间点:

术后恢复室内

测量方法:

实时记录

Measure time point of outcome:

Postoperative recovery room

Measure method:

Real-time recording

指标中文名:

喉罩通气满意度评分

指标类型:

次要指标

Outcome:

Laryngeal Mask Airway Satisfaction Score

Type:

Secondary indicator

测量时间点:

喉罩置入后

测量方法:

评分量表

Measure time point of outcome:

After laryngeal mask insertion

Measure method:

Rating scale

指标中文名:

喉罩密封压

指标类型:

次要指标

Outcome:

Laryngeal mask sealing pressure

Type:

Secondary indicator

测量时间点:

喉罩置入后

测量方法:

仪器测量

Measure time point of outcome:

After laryngeal mask insertion

Measure method:

Instrument measurement

指标中文名:

术后咽喉部视觉模拟量表疼痛评分

指标类型:

次要指标

Outcome:

Postoperative Visual Analog Scale Pain Score for Throat

Type:

Secondary indicator

测量时间点:

手术后

测量方法:

评分量表

Measure time point of outcome:

Postoperative

Measure method:

Rating scale

指标中文名:

咽部阻力评分

指标类型:

主要指标

Outcome:

Pharyngeal resistance score

Type:

Primary indicator

测量时间点:

插喉罩时

测量方法:

评分量表

Measure time point of outcome:

When inserting a laryngeal mask

Measure method:

Rating scale

指标中文名:

气道应激事件

指标类型:

次要指标

Outcome:

Airway stress event

Type:

Secondary indicator

测量时间点:

喉罩置入后

测量方法:

实时记录

Measure time point of outcome:

After laryngeal mask insertion

Measure method:

Real-time recording

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用计算机生成的随机数字表进行随机分组,确保分组的随机性和公正性。每位入组患者将在诱导前获得一个随机数字,并根据该数字被分配至A组、B组或C组。随机过程将由一名不参与患者麻醉和喉罩置入的独立研究人员执行,以确保研究的盲态和结果的客观性。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random grouping was conducted using a computer-generated random number table to ensure the randomness and fairness of the grouping. Each enrolled patient would be assigned a random number before induction and be allocated to Group A, B or C based on this number. The randomization process would be carried out by an independent researcher who was not involved in the anesthesia and laryngeal mask insertion of the patients, to ensure the blinding of the study and the objectivity of the results.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

三盲(受试者盲、研究者盲、数据分析者盲)

Blinding:

The triple-blind design includes Blinding of Subjects,Researchers and Data Analysts

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

为提高研究的可信度和推进临床发展,本研究的数据将会有条件的公开。公开的数据为去标识化。研究结束6个月后,其他研究者可通过联系本研究负责人邮箱(nblylmz@126.com)获取原始数据。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

To enhance the credibility of the research and advance clinical development, the data from this study will be conditionally disclosed. The disclosed data will be de-identified. Six months after the conclusion of the study, other researchers may obtain the original data by contacting the principal investigator via email (nblylmz@126.com).

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

所有数据将由专门的研究者进行记录和整理,采用电子数据进行存储和管理,设有权限控制,确保数据的保密性和安全性。研究期间,将定期对数据进行核查和清理,以确保数据的准确性和完整性。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

All data will be recorded and organized by dedicated researchers, stored and managed electronically, with access control in place to ensure the confidentiality and security of the data. During the research period, data will be regularly checked and cleaned to ensure its accuracy and completeness.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-03-16 10:35:16